|Bid||12.25 x 1200|
|Ask||13.56 x 2200|
|Day's Range||11.73 - 12.86|
|52 Week Range||4.03 - 13.04|
|Beta (5Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2021 - Mar 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.50|
The big shareholder groups in Celcuity Inc. ( NASDAQ:CELC ) have power over the company. Institutions will often hold...
\\- UCLA Jonsson Comprehensive Cancer Center and Vanderbilt-Ingram Cancer Center will also participate\\- Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-positive, HER2-negative breast cancer patients selected by the CELsignia® TestMINNEAPOLIS, MN / ACCESSWIRE / December 23, 2020 / Celcuity Inc.
-New clinical trial collaborations with pharmaceutical companies on track to close-Cash burn rate steady-Cash and cash equivalents of $13.